Mild electrical stimulation with heat shock attenuates renal pathology in adriamycin-induced nephrotic syndrome mouse model.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
30 10 2020
Historique:
received: 12 05 2020
accepted: 20 10 2020
entrez: 31 10 2020
pubmed: 1 11 2020
medline: 4 3 2021
Statut: epublish

Résumé

Nephrotic syndrome (NS) is a renal disorder that is characterized by massive proteinuria, hypoalbuminemia and edema. One of the main causes of NS is focal segmental glomerulosclerosis (FSGS), which has extremely poor prognosis. Although steroids and immunosuppressants are the first line of treatment, some FSGS cases are refractory, prompting the need to find new therapeutic strategies. We have previously demonstrated that an optimized combination treatment of mild electrical stimulation (MES) and heat shock (HS) has several biological benefits including the amelioration of the pathologies of the genetic renal disorder Alport syndrome. Here, we investigated the effect of MES + HS on adriamycin (ADR)-induced NS mouse model. MES + HS suppressed proteinuria and glomerulosclerosis induced by ADR. The expressions of pro-inflammatory cytokines and pro-fibrotic genes were also significantly downregulated by MES + HS. MES + HS decreased the expression level of cleaved caspase-3 and the number of TUNEL-positive cells, indicating that MES + HS exerted anti-apoptotic effect. Moreover, MES + HS activated the Akt signaling and induced the phosphorylation and inhibition of the apoptotic molecule BAD. In in vitro experiment, the Akt inhibitor abolished the MES + HS-induced Akt-BAD signaling and anti-apoptotic effect in ADR-treated cells. Collectively, our study suggested that MES + HS modulates ADR-induced pathologies and has renoprotective effect against ADR-induced NS via regulation of Akt-BAD axis.

Identifiants

pubmed: 33128027
doi: 10.1038/s41598-020-75761-8
pii: 10.1038/s41598-020-75761-8
pmc: PMC7603347
doi:

Substances chimiques

Cytokines 0
Doxorubicin 80168379AG
Creatinine AYI8EX34EU
Casp3 protein, mouse EC 3.4.22.-
Caspase 3 EC 3.4.22.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

18719

Références

J Biol Chem. 2013 May 31;288(22):16117-26
pubmed: 23599430
Pediatric Health Med Ther. 2017 Apr 11;8:29-37
pubmed: 29388620
Kidney Int. 1994 Feb;45(2):525-36
pubmed: 8164441
Clin Exp Nephrol. 2003 Dec;7(4):255-9
pubmed: 14712353
Curr Protoc Immunol. 2015 Feb 02;108:15.28.1-15.28.6
pubmed: 25640989
J Biol Chem. 2014 Sep 19;289(38):26143-54
pubmed: 25081543
Int J Hyperthermia. 2009 Dec;25(8):655-60
pubmed: 20021226
J Clin Invest. 2014 Apr;124(4):1608-21
pubmed: 24590287
Kidney Int. 2001 Sep;60(3):957-68
pubmed: 11532090
Cancer Biol Ther. 2005 Feb;4(2):139-63
pubmed: 15725726
J Surg Res. 2010 Aug;162(2):213-20
pubmed: 19665146
Sci Rep. 2016 Oct 19;6:35690
pubmed: 27759092
Kidney Int. 2000 Oct;58(4):1797-804
pubmed: 11012915
Clin J Am Soc Nephrol. 2015 Apr 7;10(4):592-600
pubmed: 25635037
Exp Cell Res. 1997 Oct 10;236(1):248-58
pubmed: 9344605
Clin J Am Soc Nephrol. 2014 Mar;9(3):626-32
pubmed: 23990165
J Am Soc Nephrol. 2005 Oct;16(10):2941-52
pubmed: 16107576
Nat Commun. 2014;5:3296
pubmed: 24526233
Semin Nephrol. 2009 Jul;29(4):389-98
pubmed: 19615560
EBioMedicine. 2014 Nov 11;1(1):80-9
pubmed: 26137510
Nephrology (Carlton). 2011 Jan;16(1):30-8
pubmed: 21175974
Clin J Am Soc Nephrol. 2010 Nov;5(11):2115-21
pubmed: 20966123
Clin J Am Soc Nephrol. 2014 Mar;9(3):609-16
pubmed: 23813556
Pain. 2006 Jan;120(1-2):182-7
pubmed: 16360266
Pediatr Nephrol. 2020 Jan;35(1):17-24
pubmed: 30564879
J Am Soc Nephrol. 2002 Dec;13(12):3005-15
pubmed: 12444221
Eplasty. 2008 May 16;8:e28
pubmed: 18552975
Cell. 1997 Oct 17;91(2):231-41
pubmed: 9346240
Nephrol Dial Transplant. 2012 Oct;27(10):3762-70
pubmed: 22555250
PLoS One. 2012;7(8):e43852
pubmed: 22937108
Pediatr Int. 2016 Mar;58(3):219-23
pubmed: 26275234
Intern Med. 2012;51(7):759-62
pubmed: 22466834
Med Hypotheses. 2007;68(4):900-5
pubmed: 17184932
J Am Soc Nephrol. 2009 Jan;20(1):114-22
pubmed: 19073829
Nature. 2006 Jul 27;442(7101):457-60
pubmed: 16871217
Cell Mol Life Sci. 2020 Jul;77(14):2681-2699
pubmed: 31974658
Lancet. 2014 Oct 4;384(9950):1273-81
pubmed: 24965823
Obes Res Clin Pract. 2010 Apr-Jun;4(2):e83-e162
pubmed: 24345648
Nephrol Dial Transplant. 2018 Feb 1;33(2):214-223
pubmed: 28992339
Am J Kidney Dis. 2001 Apr;37(4):820-31
pubmed: 11273883
PLoS One. 2008;3(12):e4068
pubmed: 19114996
Exp Dermatol. 2018 Oct;27(10):1092-1097
pubmed: 29928760
J Am Soc Nephrol. 2014 Nov;25(11):2393-8
pubmed: 24854282
Cell Tissue Res. 2017 Jul;369(1):237-244
pubmed: 28361304
Expert Opin Pharmacother. 2005 Aug;6(9):1539-49
pubmed: 16086641
Clin J Am Soc Nephrol. 2017 Mar 7;12(3):502-517
pubmed: 28242845

Auteurs

Keisuke Teramoto (K)

Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto, Kumamoto, 862-0973, Japan.
Program for Leading Graduate Schools "HIGO (Health Life Science: Interdisciplinary and Global Oriented) Program", Kumamoto University, Kumamoto, Japan.

Yu Tsurekawa (Y)

Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto, Kumamoto, 862-0973, Japan.
Program for Leading Graduate Schools "HIGO (Health Life Science: Interdisciplinary and Global Oriented) Program", Kumamoto University, Kumamoto, Japan.

Mary Ann Suico (MA)

Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto, Kumamoto, 862-0973, Japan.
Global Center for Natural Resources Sciences, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto, Kumamoto, 862-0973, Japan.

Shota Kaseda (S)

Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto, Kumamoto, 862-0973, Japan.
Program for Leading Graduate Schools "HIGO (Health Life Science: Interdisciplinary and Global Oriented) Program", Kumamoto University, Kumamoto, Japan.

Kohei Omachi (K)

Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto, Kumamoto, 862-0973, Japan.
Program for Leading Graduate Schools "HIGO (Health Life Science: Interdisciplinary and Global Oriented) Program", Kumamoto University, Kumamoto, Japan.

Tsubasa Yokota (T)

Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto, Kumamoto, 862-0973, Japan.

Misato Kamura (M)

Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto, Kumamoto, 862-0973, Japan.
Program for Leading Graduate Schools "HIGO (Health Life Science: Interdisciplinary and Global Oriented) Program", Kumamoto University, Kumamoto, Japan.

Mariam Piruzyan (M)

Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto, Kumamoto, 862-0973, Japan.
Program for Leading Graduate Schools "HIGO (Health Life Science: Interdisciplinary and Global Oriented) Program", Kumamoto University, Kumamoto, Japan.

Tatsuya Kondo (T)

Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, Kumamoto, 860-8556, Japan.

Tsuyoshi Shuto (T)

Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto, Kumamoto, 862-0973, Japan.
Global Center for Natural Resources Sciences, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto, Kumamoto, 862-0973, Japan.

Eiichi Araki (E)

Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, Kumamoto, 860-8556, Japan.

Hirofumi Kai (H)

Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto, Kumamoto, 862-0973, Japan. hirokai@gpo.kumamoto-u.ac.jp.
Program for Leading Graduate Schools "HIGO (Health Life Science: Interdisciplinary and Global Oriented) Program", Kumamoto University, Kumamoto, Japan. hirokai@gpo.kumamoto-u.ac.jp.
Global Center for Natural Resources Sciences, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto, Kumamoto, 862-0973, Japan. hirokai@gpo.kumamoto-u.ac.jp.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH